MYD88 Mutations and Sensitivity to Ibrutinib Therapy Reply

Bobee Victor; Ruminy Philippe; Marchand Vinciane; Viailly Pierre-Julien; Sater Ahmad Abdel; Veresezan Liana; Drieux Fanny; Berard Caroline; Bohers Elodie; Mareschal Sylvain; Dubois Sydney; Jais Jean-Philippe; Leroy Karen; Figeac Martin; Picquenot Jean-Michel; Molina Thierry J.; Salles Gilles; Haioun Corinne; Tilly Herve; Jardin Fabrice

首页> 外文期刊>The Journal of molecular diagnostics: JMD >MYD88 Mutations and Sensitivity to Ibrutinib Therapy Reply

【24h】

MYD88 Mutations and Sensitivity to Ibrutinib Therapy Reply

机译：MyD88突变和对Ibrutinib治疗答复的敏感性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《The Journal of molecular diagnostics: JMD》 |2018年第2期|共1页
作者
Bobee Victor; Ruminy Philippe; Marchand Vinciane; Viailly Pierre-Julien; Sater Ahmad Abdel; Veresezan Liana; Drieux Fanny; Berard Caroline; Bohers Elodie; Mareschal Sylvain; Dubois Sydney; Jais Jean-Philippe; Leroy Karen; Figeac Martin; Picquenot Jean-Michel; Molina Thierry J.; Salles Gilles; Haioun Corinne; Tilly Herve; Jardin Fabrice;
展开▼
作者单位

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Univ Normandie UNIROUEN LITIS Lab Informat &

Traitement Informat EA 4108 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Hop Necker Enfants Malad AP HP INSERM UMRS 872 Paris France;

Hop Necker Enfants Malad AP HP INSERM UMRS 872 Paris France;

Univ Lille Ctr Biol &

Pathol Lille France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Univ Paris Descartes Sorbonne Cite Necker Hosp AP HP Dept Pathol Paris France;

Univ Claude Bernard Lyon 1 Hosp Civils Lyon Lyon France;

Hosp Henri Mondor Creteil France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

Ctr Henri Becquerel INSERM U1245 Team 03 Rouen France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类临床医学;
关键词

相似文献

外文文献
中文文献
专利

1. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies [J] . Yonghui Sun, Wanli Liu, Yu Rao, 细胞研究（英文版） . 2018,第007期
2. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients [J] . WU Xue-yan, MAO Jiang-feng, LU Shuang-yu, 中华医学杂志：英文版 . 2009,第023期
3. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients [J] . WU Xue-yan, MAO Jiang-feng, LU Shuang-yu, 中华医学杂志（英文版） . 2009,第023期
4. Expression and Prognosis of MYD88 L265p Mutation in Diffuse Large B-Cell Lymphoma [J] . Yiming Zhao, Rui Zhang, Ling Ge, 血液病期刊（英文） . 2020,第004期
5. Reply to"Can femoral head necrosis induced by steroid therapy in patients infected with coronaviruses be reversed?" [J] . Peixun Zhang, Jiabao Ju, Na Han, 骨研究（英文版） . 2021,第002期
6. MYD88 Mutations and Sensitivity to Ibrutinib Therapy Reply [J] . Bobee Victor, Ruminy Philippe, Marchand Vinciane, The Journal of molecular diagnostics: JMD . 2018,第2期

机译：MyD88突变和对Ibrutinib治疗答复的敏感性
7. MYD88 Mutations and Sensitivity to Ibrutinib Therapy [J] . Wang Y. Lynn The Journal of molecular diagnostics: JMD . 2018,第2期

机译：MyD88突变和对Ibrutinib治疗的敏感性
8. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation [J] . Castillo Jorge J., Ghobrial Irene M., Treon Steven P. Leukemia and lymphoma . 2016,第11期

机译：携带MYD88 L265P基因突变的IgG淋巴浆细胞性淋巴瘤患者对依鲁替尼的反应
9. Comparison of Three Laboratory-Developed Tests for Detection of the MYD88 L265P Mutation in Differential Diagnosis of Waldenstrom Macroglobulinemia [C] . Kok Siong Poon, Te Chih Liu, Evelyn Siew Chuan Koay Molecular Medicine TRI-CON.;Conferences healthtech . 2014

机译：三种实验室开发的试验检测核核胰岛血症差异诊断中的三种实验室开发的试验
10. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
11. Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation [O] . Francesca Maria Quaglia, Gian Matteo Rigolin, Elena Saccenti, 2019

机译：携带MYD88 L265P基因突变的难治性IgA淋巴浆细胞性淋巴瘤对依鲁替尼的反应
12. PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRöM MACROGLOBULINEMIA WITH MYD88 AND CXCR4 MUTATIONS [O] . S. Treon, C. Buske, S. Thomas, 2021

机译：来自沃尔德斯·莫尔登莫甲基胰岛素血症患者Manavexafor和Ibrutinib患者的初步临床资料，MyD88和CXCR4突变
13. Development of Targeted Molecular Therapy for Cancers Harboring BAP1 Mutations. [R] . Harbour, J. W., Kuznetsov, J., King, M. L., 2016

机译：针对携带Bap1突变的癌症的靶向分子疗法的开发。

MYD88 Mutations and Sensitivity to Ibrutinib Therapy Reply

著录项

引文网络

相似文献

相关主题

期刊订阅